Literature DB >> 11584690

Hepatitis C: an update.

D Moradpour1, A Cerny, M H Heim, H E Blum.   

Abstract

Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. While current therapeutic options for hepatitis C are limited, recent progress in the understanding of the biology of HCV led to the identification of novel targets for antiviral intervention. In addition, molecular and immunotherapeutic strategies to inhibit HCV replication or gene expression and to enhance the cellular immune response against HCV are being explored. These and other novel antiviral strategies may eventually complement existing therapeutic modalities. Here, we briefly review current concepts of the epidemiology, molecular virology, pathogenesis, natural history, diagnosis, therapy, and prevention of hepatitis C.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11584690     DOI: 2001/21/smw-06097

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  9 in total

1.  Generation of the regulatory protein rtTA transgenic mice.

Authors:  Kang Xu; Xin-Yan Deng; Ying Yue; Zhong-Min Guo; Bing Huang; Xun Hong; Dong Xiao; Xi-Gu Chen
Journal:  World J Gastroenterol       Date:  2005-05-21       Impact factor: 5.742

2.  Risk factors for hepatitis C virus infection among blood donors in Georgia.

Authors:  Nickolas Zaller; Kenrad E Nelson; Malvina Aladashvili; Nino Badridze; Carlos del Rio; Tengiz Tsertsvadze
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

3.  Evaluation of Versant hepatitis C virus genotype assay (LiPA) 2.0.

Authors:  Jannick Verbeeck; Mark J Stanley; Jen Shieh; Linda Celis; Els Huyck; Elke Wollants; Judy Morimoto; Alice Farrior; Erwin Sablon; Margaret Jankowski-Hennig; Carl Schaper; Pamela Johnson; Marc Van Ranst; Marianne Van Brussel
Journal:  J Clin Microbiol       Date:  2008-04-09       Impact factor: 5.948

4.  Strategic approach to produce low-cost, efficient, and stable competitive internal controls for detection of RNA viruses by use of reverse transcription-PCR.

Authors:  Gabriela V Villanova; Daniela Gardiol; Miguel A Taborda; Virginia Reggiardo; Hugo Tanno; Emilia D Rivadeneira; Germán R Perez; Adriana A Giri
Journal:  J Clin Microbiol       Date:  2007-08-15       Impact factor: 5.948

5.  Cytoskeletal requirements for hepatitis C virus (HCV) RNA synthesis in the HCV replicon cell culture system.

Authors:  Anne G Bost; Daryl Venable; Lifei Liu; Beverly A Heinz
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

6.  New insights regarding HCV-NS5A structure/function and indication of genotypic differences.

Authors:  Lilian Ht Yamasaki; Helen A Arcuri; Ana Carolina G Jardim; Cintia Bittar; Isabel Maria Vg de Carvalho-Mello; Paula Rahal
Journal:  Virol J       Date:  2012-01-12       Impact factor: 4.099

7.  Chemical proteomic identification of T-plastin as a novel host cell response factor in HCV infection.

Authors:  Young-Hwa Yoo; JiHyeon Yun; Chang No Yoon; Jun-Seok Lee
Journal:  Sci Rep       Date:  2015-04-24       Impact factor: 4.379

8.  High Rates of Hepatitis B and C and HIV Infections among Blood Donors in Cameroon: A Proposed Blood Screening Algorithm for Blood Donors in Resource-Limited Settings.

Authors:  Florent Fouelifack Ymele; Basile Keugoung; Jeanne Hortense Fouedjio; Nadege Kouam; Sandrine Mendibi; Jacqueline Dongtsa Mabou
Journal:  J Blood Transfus       Date:  2012-09-19

9.  Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a.

Authors:  Isabelle Moreau; John Levis; Orla Crosbie; Elizabeth Kenny-Walsh; Liam J Fanning
Journal:  Virol J       Date:  2008-07-09       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.